Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06756035 · ClinicalTrials.gov registry record · Phase 1
CT-95 in Advanced Cancers Associated With Mesothelin Expression
A Phase 1 study of Epithelial Ovarian Cancer and Cholangiocarcinoma Non-resectable, sponsored by Context Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT06756035: Recruiting Phase 1 study of Epithelial Ovarian Cancer and Cholangiocarcinoma Non-resectable, sponsored by Context Therapeutics.
NCT06756035 is a Phase 1 study of Epithelial Ovarian Cancer and Cholangiocarcinoma Non-resectable that is actively recruiting participants, run by Context Therapeutics. The registered enrollment target is 70 participants, below the 209-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (67% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06756035, a Phase 1 study of Epithelial Ovarian Cancer and Cholangiocarcinoma Non-resectable, is actively recruiting participants, sponsored by Context Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
Primary Outcome
The frequency of dose-limiting toxicities (DLTs) will be analyzed along with safety and tolerability measures to determine the MTD or RD of CT-95.
Conditions Studied
Interventions
- DRUG CT-95
Study Locations (8)
Texas
- Context Investigational Site - San Antonio
- Context Investigational Site - San Antonio
Colorado
- Context Investigational Site - Denver
Illinois
- Context Investigational Site - Chicago
Michigan
- Context Investigational Site - Grand Rapids
New Jersey
- Context Investigational Site - Hackensack
Pennsylvania
- Context Investigational Site - Philadelphia
Tennessee
- Context Investigational Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06756035 shows while recruiting
NCT06756035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 209-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (67% lower).
The record links to 10 conditions, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which CT-95 is the first listed.
NCT06756035 lists 8 locations in 7 states (Texas, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT06756035 about?
NCT06756035 is a clinical study titled "CT-95 in Advanced Cancers Associated With Mesothelin Expression". This is a Phase 1a/1b open-label, dose escalation study to evaluate the safety and efficacy of CT-95 (study drug), a humanized T cell engaging bispecific antibody targeting Mesothelin, in subjects with advanced solid tumors associated with Mesothelin expression.
What is the current status of trial NCT06756035?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-03-31. Estimated completion is 2028-12.
What conditions does trial NCT06756035 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer, Cholangiocarcinoma Non-resectable, Lung Adenocarcinoma Metastatic, Mesothelin-Expressing Tumors, Malignant Pleural Mesothelioma, Advanced.
What interventions are being tested in trial NCT06756035?
The interventions under investigation include: CT-95 (DRUG).
Who is sponsoring clinical trial NCT06756035?
This trial is sponsored by Context Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06756035 being conducted?
This trial has 8 study locations across Colorado, Illinois, Michigan, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06756035's enrollment target sits among peer trials
70 24th of 41 higher than 16 of 41 other Epithelial Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epithelial Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI